Compare iShares MBS ETF (MBB) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MBS ETF vs Tilray Brands Inc — how do they compare? iShares MBS ETF trades at $89.53 (market cap $35.41B), while Tilray Brands Inc trades at $3.53 (market cap $530.54M). The key difference: iShares MBS ETF is far larger — about 66.7× Tilray Brands Inc's market cap, and Tilray Brands Inc is more actively traded (9,099,075 versus 5,388,525). Which is the better fit depends on your goals — on Pluang, investors hold iShares MBS ETF for 96 Days and Tilray Brands Inc for 31 Days on average.
| MBB | TLRY | |
|---|---|---|
Market Cap | $35.41B | $530.54M |
Volume | 5,388,525 | 9,099,075 |
Sector | Fixed Income | Health |
52-Week High | $96.91 | $21.00 |
52-Week Low | $89.09 | $3.57 |
Typical Hold Time | 96 Days | 31 Days |
Enterprise Value | — | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MBB (iShares MBS ETF) trades at $89.22, down 0.16% amid bearish technical signals with 18 sell indicators versus 2 buy signals. The ETF faces pressure from rising intermediate-term rates and inflation concerns, with short interest surging 98.3% in September 2026 to 6.57 million shares. Recent institutional activity shows mixed sentiment with some firms increasing positions while technical indicators point to continued downward momentum.
The outlook remains challenging with convexity risk and borrower prepayment optionality limiting upside potential. Investment opportunity exists for income-focused investors through consistent dividend payments, but risks include duration exposure during potential rate hikes and persistent inflation pressures affecting mortgage-backed securities performance.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
